Feb 14, 2023 / 03:00PM GMT
Marc Goodman - SVB Securities - Analyst
Okay. Welcome back, everybody, for our next session at the SVB Securities Healthcare Conference. We are lucky enough to have the management team of Amylyx. We have Josh Cohen and Justin Klee, the two co-founders; and Jim Frates, who is the CFO.
We've been supporters of this company since they went public. There's not a lot of ALS drugs out there, and this is a really good drug. And we think it's been a [great move] quite a bit on top of standard of care. So we've been very positive on this thing for quite a while. And it's so much great to have them here.
There was a filing that went out, the SEC filing this morning. And so I'm going to throw this over to Josh. He is going to kick off a little bit and probably just give a little comment on what went into that release so we're all level set. And thanks again for everybody joining us. Go ahead, Josh.
Josh Cohen - Amylyx Pharmaceuticals, Inc. - Co-CEO & Co-Founder
Yeah. Thank you so much, Marc, and good morning, and really appreciate you hosting us
Amylyx Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers